Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Nikko Asset Management Americas Inc.

Nikko Asset Management Americas Inc. cut its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 8.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,908,651 shares of the company’s stock after selling 786,127 shares during the period. Nikko Asset Management Americas Inc. owned approximately 2.28% of Recursion Pharmaceuticals worth $60,133,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Decker Retirement Planning Inc. acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter worth $26,000. Private Trust Co. NA acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at $27,000. GAMMA Investing LLC boosted its position in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after purchasing an additional 4,948 shares during the period. KBC Group NV boosted its position in shares of Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after purchasing an additional 3,377 shares during the period. Finally, Farther Finance Advisors LLC boosted its position in shares of Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock valued at $52,000 after purchasing an additional 1,353 shares during the period. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX opened at $6.35 on Monday. Recursion Pharmaceuticals, Inc. has a 1-year low of $5.60 and a 1-year high of $12.36. The firm has a market capitalization of $2.55 billion, a PE ratio of -4.15 and a beta of 0.85. The business’s 50 day moving average is $7.54 and its 200-day moving average is $7.02. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The firm had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s revenue for the quarter was down 57.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.42) EPS. Sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Leerink Partners decreased their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Friday, February 28th. KeyCorp decreased their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $8.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.